Stockscreener 앱 받기
53.20
2.33%
1.21
시간 외 거래:
53.20
전일 마감가:
$51.99
열려 있는:
$52.26
하루 거래량:
1.16M
Relative Volume:
0.95
시가총액:
$5.14B
수익:
$7.50M
순이익/손실:
$-383.17M
주가수익비율:
-11.31
EPS:
-4.7048
순현금흐름:
$-307.84M
1주 성능:
+3.62%
1개월 성능:
-2.19%
6개월 성능:
+23.69%
1년 성능:
+67.82%
1일 변동 폭
$52.11
$53.83
1주일 범위
$51.11
$53.83
52주 변동 폭
$30.00
$63.95
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
명칭
Xenon Pharmaceuticals Inc
전화
(604) 484-3300
주소
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
53.20 | 5.07B | 7.50M | -383.17M | -307.84M | -4.7048 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2025-09-03 | 재개 | Wells Fargo | Overweight |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-01 | 개시 | H.C. Wainwright | Buy |
| 2024-01-04 | 개시 | Citigroup | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-04-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-14 | 개시 | Goldman | Buy |
| 2022-12-12 | 개시 | Cowen | Outperform |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-10-19 | 개시 | Raymond James | Outperform |
| 2022-08-29 | 개시 | BofA Securities | Buy |
| 2022-07-21 | 개시 | JP Morgan | Overweight |
| 2021-10-28 | 개시 | RBC Capital Mkts | Outperform |
| 2020-10-02 | 개시 | SVB Leerink | Outperform |
| 2020-07-21 | 개시 | Needham | Buy |
| 2020-06-01 | 재개 | Jefferies | Buy |
| 2020-03-25 | 개시 | Wedbush | Outperform |
| 2020-01-08 | 개시 | William Blair | Outperform |
| 2019-09-20 | 개시 | Guggenheim | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2017-03-13 | 개시 | Jefferies | Buy |
| 2016-10-21 | 개시 | Stifel | Buy |
| 2016-09-26 | 개시 | Guggenheim | Buy |
| 2016-04-14 | 재확인 | Jefferies | Buy |
| 2015-10-30 | 재개 | Jefferies | Buy |
| 2014-12-02 | 개시 | Canaccord Genuity | Buy |
모두보기
Xenon Pharmaceuticals Inc 주식(XENE)의 최신 뉴스
Assessing Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Pullback And Modest Undervaluation Estimate - Yahoo Finance
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight - GlobeNewswire Inc.
Fiera Capital Corp Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals (XENE) director Cannon sells 1,190 shares under 10b5-1 tax plan - Stock Titan
Xenon (XENE) director Patou sells 1,322 shares in tax-related 10b5-1 trade - Stock Titan
[144] Xenon Pharmaceuticals Inc. SEC Filing - Stock Titan
Xenon Pharmaceuticals (XENE) director receives new RSUs, options and RSU vesting - Stock Titan
Xenon Pharmaceuticals (XENE) director awarded RSUs, options and exercises vested RSUs - Stock Titan
Xenon Pharmaceuticals (XENE) director receives RSUs, options and nets vested shares - Stock Titan
Xenon Pharmaceuticals (XENE) investors approve 2026 equity plan and pay votes - Stock Titan
Xenon Pharmaceuticals (XENE) director exercises RSUs and gets new option award - Stock Titan
Xenon Q1 earnings match estimates, pipeline development in focus - MSN
Xenon Pharmaceuticals Inc. Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Xenon Pharmaceuticals Inc. Rings the Opening Bell - Nasdaq
Wells Fargo Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $69 - Moomoo
Assessing Xenon Pharmaceuticals (XENE) Valuation After A Recent Pullback And Strong Multi Year Returns - Sahm
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xenon Pharmaceuticals reports inducement grants under Nasdaq Listing Rule - marketscreener.com
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
XENE Q1 2026 Earnings: EPS Beat Amid Continued Clinical Development FocusOne-Time Gain Impact - newsline.com
J.P. Morgan Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Raises Target Price to $82 - Moomoo
XENE Maintains Overweight Rating -- Price Target Raised to $82.0 - GuruFocus
Xenon Pharmaceuticals (XENE) Edges Higher Amidst Neutral TradingFactor ETF Flow - thelegaladvocate.com
Trading the Move, Not the Narrative: (XENE) Edition - Stock Traders Daily
Xenon Pharmaceuticals (XENE) Holds Near Support Amid Modest PullbackVolatility Skew - thelegaladvocate.com
JPMorgan Raises its Price Target on Xenon Pharmaceuticals (XENE) - Insider Monkey
Xenon Pharmaceuticals Inc.Common Shares (NQ: XENE - The Chronicle-Journal
5 Best Performing Canadian Stocks So Far in 2026 - Insider Monkey
A Look At Xenon Pharmaceuticals (XENE) Valuation After Strong Long Term Returns And Recent Momentum Cooldown - Sahm
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing - AOL.com
Which Is a Better Investment, Sarepta Therapeutics, Inc. or Xenon Pharmaceuticals Inc. Stock? - AAII
Xenon Pharmaceuticals stock (CA98420N1050): epilepsy data and capital raise put biotech in focus - AD HOC NEWS
DNB Asset Management AS Acquires 23,750 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
(XENE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Janus Henderson reports 4.5% stake in Xenon Pharmaceuticals (XENE) filing - Stock Titan
Xenon Pharmaceuticals (NASDAQ: XENE) shows 5.78M-share holding, 6.26% - Stock Titan
Driehaus files Schedule 13G/A disclosing 4.87% in Xenon (XENE) - Stock Titan
XENE: Azetukalner’s strong efficacy and novel mechanism set the stage for a major epilepsy market launch - TradingView
Xenon Pharmaceuticals stock (CA98420N1050): Director exercises options for 3,500 shares - AD HOC NEWS
Xenon Pharmaceuticals (XENE) director exercises options, now holds 10,641 shares - Stock Titan
XENE Maintained by JP Morgan -- Price Target Raised to $80.00 - GuruFocus
Xenon Pharmaceuticals Is Maintained at Overweight by JP Morgan - Moomoo
Xenon anticipates AZK NDA in Q3 2026 amid launch timing at end of 2027 or early 2028 - MSN
Equities Analysts Set Expectations for XENE Q2 Earnings - MarketBeat
A Look At Xenon Pharmaceuticals (XENE) Valuation After Phase 3 X TOLE2 Success And Extended Cash Runway - Yahoo Finance
Insiders At Xenon Pharmaceuticals Sold US$1.0m In Stock, Alluding To Potential Weakness - Moomoo
Did Positive X-TOLE2 Data and a Major Cash Raise Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative? - Yahoo Finance
Xenon Pharmaceuticals Inc (XENE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Xenon Pharmaceuticals Inc 주식 (XENE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Cannon Gillian | Director |
Jun 05 '26 |
Sale |
53.14 |
1,190 |
63,237 |
1,455 |
2.60%
0.94%
자본화:
|
볼륨(24시간):